Accessibility Menu
Radiopharm Theranostics logo

Radiopharm Theranostics(ASX) RAD

Market CapA$43.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-97%
5 YearN/A
1 Year-69%
1 Month-25%
A$0.01
-10.00%
-0.00Today
Radiopharm Theranostics last closing stock price
MetricPriceDate
Last closeAUD 0.012026-09-08
Radiopharm Theranostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10%AUD 0.012026-09-01
1 month-25%AUD 0.012026-08-07
3 month-55%AUD 0.022026-06-10
Year to date-64%AUD 0.032025-12-31
1 year-68.97%AUD 0.032025-09-08
3 year-91.82%AUD 0.112023-09-08
Since inception-97.26%AUD 0.372021-11-25

Radiopharm Theranostics Financials at a Glance

Market Cap

A$43.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$16.17M

Net Income (TTM)

-A$91.85M

EPS (TTM)

-A$0.02

P/E Ratio

-0.64

Dividend

A$0.00

Beta (Volatility)

-0.13 (Low)

Price

A$0.01

Volume

1,814,096

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.04

Estimated Earnings Date

Feb 26, 2027

RAD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Radiopharm Theranostics

Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company focused on developing radiopharmaceutical products for diagnostic and therapeutic applications. The company aims to address significant unmet medical needs through innovative solutions in the biotechnology sector.

Products and Services
  • RAD101: Pivalate brain metastasis diagnostic
  • RAD102: Pivalate therapeutic for brain metastasis
  • RAD201a: Nano-mAb HER-2 breast diagnostic
Growth Outlook
  • Strategic agreement with Lantheus Holdings to enhance clinical development
  • Expanding pipeline with multiple promising radiopharmaceuticals
  • Focus on high unmet medical needs in oncology and neurology
Financial Highlights
  • Recent quarterly revenue of 1,385,545 AUD, showing growth potential
  • Cash and cash equivalents of 34,515,397 AUD, providing operational runway
  • Current ratio of 3.01 indicates strong liquidity position
Radiopharm Theranostics Limited is positioned in a rapidly evolving biotechnology landscape, focusing on the development of innovative radiopharmaceuticals. The company’s strategic partnerships and expanding product pipeline highlight its commitment to addressing critical healthcare challenges. Recent financial data indicates a solid liquidity position, which is essential for supporting ongoing research and development efforts. The focus on high unmet medical needs in oncology and neurology further underscores the potential for significant growth in the coming years.
AI Generated • Aug 27, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Riccardo Canevari

Website

radiopharmtheranostics.com

Headquarters

Carlton, VIC 3053, AU

RAD Financials

Key Financial Metrics (TTM)

Gross Margin

-39.41%

Operating Margin

-2545.78%

Net Income Margin

-1992.46%

Return on Equity

-144.24%

Return on Capital

-276.78%

Return on Assets

-91.71%

Earnings Yield

-1.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$43.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.34B

Volume

1.81M

Avg. Volume

6.65M

Financials (TTM)

Gross Profit

A$8.72M

Operating Income

-A$108.64M

EBITDA

-A$100.76M

Operating Cash Flow

-A$89.43M

Capital Expenditure

A$30.11M

Free Cash Flow

-A$59.32M

Cash & ST Invst.

A$4.14M

Total Debt

A$0.00

Radiopharm Theranostics Performance Analysis

Radiopharm Theranostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 292,359N/A
20242024-06-30AUD 299,2282.3%
20252025-06-30AUD 3,633,4221114.3%
20262026-06-30AUD 2,767,888-23.8%
Radiopharm Theranostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31714.6%
Q42025-06-30349.8%
Q22025-12-31-87.4%
Q42026-06-30-0.2%
Radiopharm Theranostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.11-1.7%
20242024-06-30AUD -0.1216.1%
20252025-06-30AUD -0.02-85.8%
20262026-06-30AUD -0.02-11.4%
Radiopharm Theranostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3123.7%
Q42025-06-3084.1%
Q22025-12-311.3%
Q42026-06-30-5.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$1.38M

+362.0%

Gross Profit

A$160.31K

+100.7%

Gross Margin

11.60%

N/A

Market Cap

A$43.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$3.10M

N/A

Employees

14

N/A

Net Income

-A$28.18M

-21.5%

EBITDA

-A$39.36M

-115.8%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$4.14M

-77.7%

Total Debt

A$0.00

N/A

Accounts Receivable

A$17.45M

+1667.0%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-91.71%

N/A

Return on Invested Capital

-1.71%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$30.11M

-168.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DOC.AXDoctor Care Anywhere Group PLC
A$0.13+0.00%
CSX.AXCleanSpace Holdings Limited
A$0.43-2.30%
CTE.AXCryosite Limited
A$1.25+0.00%
NSB.AXNeuroScientific Biopharmaceuticals Limited
A$0.06-1.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.03+0.03%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.34-0.10%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$117.28+0.10%
INTCIntel
$95.80+0.05%

Questions About RAD

What is the current price of Radiopharm Theranostics?

Radiopharm Theranostics is trading at A$0.01 per share.

What is the 52-week range for Radiopharm Theranostics?

Over the past 52 weeks, Radiopharm Theranostics has traded between A$0.01 and A$0.04.

How much debt does Radiopharm Theranostics have?

As of the most recent reporting period, Radiopharm Theranostics reported total debt of A$0.00.

How much cash does Radiopharm Theranostics have on hand?

Radiopharm Theranostics reported A$4.14M in cash and cash equivalents in its most recent financial results.

What is Radiopharm Theranostics’s dividend yield?

Radiopharm Theranostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services